Zoetis Inc. $ZTS Shares Purchased by AlphaCore Capital LLC

AlphaCore Capital LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 94.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,589 shares of the company’s stock after buying an additional 773 shares during the quarter. AlphaCore Capital LLC’s holdings in Zoetis were worth $248,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Zoetis by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after buying an additional 330,823 shares during the last quarter. Geode Capital Management LLC grew its stake in Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after buying an additional 95,294 shares during the last quarter. Polen Capital Management LLC increased its position in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp increased its position in Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after buying an additional 78,508 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS opened at $122.80 on Tuesday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $181.85. The stock has a market cap of $54.12 billion, a P/E ratio of 21.14, a P/E/G ratio of 2.31 and a beta of 0.90. The stock’s 50 day simple moving average is $137.28 and its 200 day simple moving average is $149.86. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the business earned $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. BTIG Research decreased their price objective on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. JPMorgan Chase & Co. decreased their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Argus restated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, UBS Group dropped their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.